Incyte Corp.

Incyte Corp.
Stock Exchange Frankfurt Stock Exchange
EPS
EUR1.02
Market Cap
EUR16.33 B
Shares Outstanding
212.58 M
Public Float
142.29 M
Incyte Corp.
Stock Exchange NASDAQ Stock Market
EPS
$1.17
Market Cap
$18.29 B
Shares Outstanding
214.44 M
Public Float
212.39 M

Profile

Address
1801 Augustine Cut-Off
Wilmington Delaware 19803
United States
Employees -
Website http://www.incyte.com
Updated 07/08/2019
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A.

Financials

View All
Created with Highcharts 5.0.14Incyte Corp.Net Income. Fiscal year is January-December. All values USD Millions.83834848771041043133131091092013201420152016201720180100200300400
Created with Highcharts 5.0.14Incyte Corp.Sales/Revenue. Fiscal year is January-December. All values USD Millions.3553555115117547541 1061 1061 5361 5361 8821 8822013201420152016201720180500100015002000

Hervé Hoppenot
Chairman, President & Chief Executive Officer
Julian Charles Baker
Lead Independent Director